COVID-19 Vaccine Adverse Reaction, Immune System Diseases, Immune System Disorder
Conditions
Brief summary
The study started after the second COVID-19 vaccination of the participant with blood spots appearing on the skin with severe arthritis. The study continued to the third-dose full vaccination of the participant with the recombined COVID-19 vaccination and afterwards. The study completed until intervention.
Interventions
None listed
Sponsors
Yang I. Pachankis, PhD
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
All COVID-19 vaccinated are eligible for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chemiluminescent Immunoassay for Human Immunodeficiency Virus | 7 months |
| Carcinoembryonic Antigen | 7 months |
| Alpha Fetoprotein | 7 months |
| Carbohydrate Antigen 19-9 | 7 months |
| Mucin-16 | 7 months |
| Cancer Antigen 15-3 | 7 months |
| Prostate-Specific Antigen | 7 months |
| Leukocytes | 7 months |
| Leukocyte Percentage | 7 months |
| Cholesterol | 7 months |
Countries
China
Outcome results
None listed